BR112014020173A8 - Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção - Google Patents
Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invençãoInfo
- Publication number
- BR112014020173A8 BR112014020173A8 BR112014020173A BR112014020173A BR112014020173A8 BR 112014020173 A8 BR112014020173 A8 BR 112014020173A8 BR 112014020173 A BR112014020173 A BR 112014020173A BR 112014020173 A BR112014020173 A BR 112014020173A BR 112014020173 A8 BR112014020173 A8 BR 112014020173A8
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- melanoma
- compositions
- inhibitor
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
MÉTODOS PARA O TRATAMENTO DE UM MELANOMA,UTILIZAÇÕES DE UM INIBIDOR, COMPOSIÇÕES, CONJUNTO, MÉTODO DE INIBIÇÃO, MÉTODO DE IDENTIFICAÇÃO, MÉTODO DE AJUSTE DO TRATAMENTO E INVENÇÃO. A presente invenção se refere aos métodos e as composições para o tratamento do melanoma utilizando um inibidor de PAK1. Em algumas realizações, a PAK1 é superexpressa e/ou amplificada no melanoma. Em algumas realizagoes, o melanoma é um melanoma de BRAFdo tipo selvagem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612202P | 2012-03-16 | 2012-03-16 | |
| PCT/EP2013/055085 WO2013135745A1 (en) | 2012-03-16 | 2013-03-13 | Methods of treating melanoma with pak1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014020173A2 BR112014020173A2 (pt) | 2017-06-20 |
| BR112014020173A8 true BR112014020173A8 (pt) | 2017-07-11 |
Family
ID=47846052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014020173A BR112014020173A8 (pt) | 2012-03-16 | 2013-03-13 | Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2844248A1 (pt) |
| JP (1) | JP2015511598A (pt) |
| KR (1) | KR20140135198A (pt) |
| CN (1) | CN104168898A (pt) |
| BR (1) | BR112014020173A8 (pt) |
| CA (1) | CA2860994A1 (pt) |
| HK (1) | HK1200093A1 (pt) |
| MX (1) | MX2014010953A (pt) |
| RU (1) | RU2014141018A (pt) |
| WO (1) | WO2013135745A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016139331A1 (en) * | 2015-03-05 | 2016-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of melanoma |
| KR101730595B1 (ko) | 2015-03-18 | 2017-05-11 | 충북대학교 산학협력단 | Pak4 억제제를 유효성분으로 포함하는 미백 및 멜라닌 색소 과다 침착 질환의 치료용 조성물 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| EP0229046B1 (fr) | 1985-03-30 | 1994-05-04 | BALLIVET, Marc | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5498538A (en) | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009300A1 (en) | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| AU7104294A (en) | 1994-06-10 | 1996-01-05 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| AU6785496A (en) | 1995-09-07 | 1997-03-27 | Novo Nordisk A/S | Phage display for detergent enzyme activity |
| PT904541E (pt) | 1996-03-20 | 2005-01-31 | Dyax Corp | Purificacao de activador de plasminogenio tecidual (tpa) |
| WO1997046251A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
| DE69731226T2 (de) | 1996-06-10 | 2006-03-09 | The Scripps Research Institute, La Jolla | Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten |
| US5766905A (en) | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
| WO1998014277A1 (en) | 1996-10-04 | 1998-04-09 | Whatman, Inc. | Device and method for simultaneous multiple chemical syntheses |
| AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| EP0938497B1 (en) | 1996-11-06 | 2007-02-28 | Genentech, Inc. | Constrained helical peptides and methods of making same |
| IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
| IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| WO2000039585A1 (en) | 1998-12-28 | 2000-07-06 | Sunesis Pharmaceuticals, Inc. | Identifying small organic molecule ligands for binding |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CA2403397A1 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| JP2006501191A (ja) | 2002-07-17 | 2006-01-12 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤としてのヘテロ二環式ピラゾール誘導体 |
| KR100919343B1 (ko) | 2005-01-10 | 2009-09-25 | 화이자 인코포레이티드 | 키네이스 억제제로서 피롤로피라졸 |
| CA2601983A1 (en) | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| CA2634381C (en) | 2005-12-21 | 2011-03-08 | Pfizer Products Inc. | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
| US20100317715A1 (en) | 2007-12-21 | 2010-12-16 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
| ES2306630B1 (es) | 2008-07-17 | 2009-06-03 | Encarnacion Mira Rodriguez | Dispositivo antiflacidez y antiarrugas. |
| US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
| EP2485727A4 (en) | 2009-10-06 | 2013-05-01 | Afraxis Inc | PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES |
| EP2486037A4 (en) | 2009-10-09 | 2013-01-16 | Afraxis Inc | 8-ETHYL-6- (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011156646A2 (en) | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| EP2580217A4 (en) | 2010-06-10 | 2014-06-18 | Afraxis Holdings Inc | 6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| US20130338153A1 (en) | 2010-06-10 | 2013-12-19 | Afraxis, Inc. | 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| US20130252967A1 (en) | 2010-06-10 | 2013-09-26 | Afraxis, Inc. | 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
-
2013
- 2013-03-13 MX MX2014010953A patent/MX2014010953A/es unknown
- 2013-03-13 CA CA2860994A patent/CA2860994A1/en not_active Abandoned
- 2013-03-13 EP EP13708841.5A patent/EP2844248A1/en not_active Withdrawn
- 2013-03-13 CN CN201380014567.8A patent/CN104168898A/zh active Pending
- 2013-03-13 RU RU2014141018A patent/RU2014141018A/ru not_active Application Discontinuation
- 2013-03-13 WO PCT/EP2013/055085 patent/WO2013135745A1/en active Application Filing
- 2013-03-13 BR BR112014020173A patent/BR112014020173A8/pt not_active IP Right Cessation
- 2013-03-13 KR KR20147025466A patent/KR20140135198A/ko not_active Application Discontinuation
- 2013-03-13 JP JP2014561427A patent/JP2015511598A/ja active Pending
-
2015
- 2015-01-16 HK HK15100513.1A patent/HK1200093A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014141018A (ru) | 2016-05-10 |
| CN104168898A (zh) | 2014-11-26 |
| CA2860994A1 (en) | 2013-09-19 |
| KR20140135198A (ko) | 2014-11-25 |
| JP2015511598A (ja) | 2015-04-20 |
| BR112014020173A2 (pt) | 2017-06-20 |
| WO2013135745A1 (en) | 2013-09-19 |
| EP2844248A1 (en) | 2015-03-11 |
| MX2014010953A (es) | 2014-10-13 |
| HK1200093A1 (en) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501987A1 (en) | Treatment of b-cell malignancies by a combination jak and p13k inhibitor | |
| BR112012032033A2 (pt) | novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase | |
| UY35787A (es) | Composiciones útiles para tratar trastornos relacionados con kit | |
| CY1121653T1 (el) | C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης | |
| MX2017003637A (es) | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). | |
| TN2015000423A1 (en) | Variants of tissue inhibitor of metalloproteinase type three (tipm-3), compositions and methods | |
| PH12014502445B1 (en) | Targeted modification of malate dehydrogenase | |
| MX2017003627A (es) | Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). | |
| UA116093C2 (uk) | Спосіб та композиція для боротьби з бур'янами (варіанти) | |
| MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| BR112013025006A2 (pt) | composições e métodos para inibição de expressão do gene tmprss6 | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| EP2603216A4 (en) | HETEROARYLE AND USES THEREOF | |
| BR112018011633A2 (pt) | inibidores de aza-benzimidazol de pad4 | |
| MX369609B (es) | Una composición para usarse en el tratamiento de cáncer deficiente en nmt2. | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| IL234483B (en) | Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same | |
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| TN2014000086A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| IN2014DN00254A (pt) | ||
| MX2013005507A (es) | Metodos para tratamiento de tumores. | |
| MX2015007608A (es) | Metodos y composiciones para inhibir cnksr1. | |
| BR112014020173A8 (pt) | Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |